User login
Key clinical point: Clonal hematopoiesis (CH) persisted after complete remission (CR) in patients with acute myeloid leukemia (AML) and was resistant to consolidation and maintenance therapies, except for allogeneic stem cell transplantation (allo-SCT). However, the presence of postremission CH did not affect clinical outcomes.
Major finding: Following induction chemotherapies, 48% of patients had post-CR CH, and it persisted in 91% of patients during and postremission chemotherapies, but disappeared in 95% of patients after allo-SCT. However, the risk for relapse (P = .174) and nonrelapse mortality (P = .827) was similar in patients with vs. without post-CR CH.
Study details: Findings are from assessment of 164 patients with AML who achieved morphological CR following induction chemotherapies.
Disclosures: This work was supported by grants from the Cancer Prevention and Research Institute of Texas, Welch Foundation, University of Texas System STARS Award, Lyda Hill Foundation, Charif Souki Cancer Research Fund, Japan Society for the Promotion of Science, Sabin Family Foundation Fellowship, and various funding programs at the MD Anderson Cancer Center. The authors declared no conflicts of interest.
Source: Tanaka T et al. Blood. 2021 Jun 3. doi: 10.1182/blood.2020010483.
Key clinical point: Clonal hematopoiesis (CH) persisted after complete remission (CR) in patients with acute myeloid leukemia (AML) and was resistant to consolidation and maintenance therapies, except for allogeneic stem cell transplantation (allo-SCT). However, the presence of postremission CH did not affect clinical outcomes.
Major finding: Following induction chemotherapies, 48% of patients had post-CR CH, and it persisted in 91% of patients during and postremission chemotherapies, but disappeared in 95% of patients after allo-SCT. However, the risk for relapse (P = .174) and nonrelapse mortality (P = .827) was similar in patients with vs. without post-CR CH.
Study details: Findings are from assessment of 164 patients with AML who achieved morphological CR following induction chemotherapies.
Disclosures: This work was supported by grants from the Cancer Prevention and Research Institute of Texas, Welch Foundation, University of Texas System STARS Award, Lyda Hill Foundation, Charif Souki Cancer Research Fund, Japan Society for the Promotion of Science, Sabin Family Foundation Fellowship, and various funding programs at the MD Anderson Cancer Center. The authors declared no conflicts of interest.
Source: Tanaka T et al. Blood. 2021 Jun 3. doi: 10.1182/blood.2020010483.
Key clinical point: Clonal hematopoiesis (CH) persisted after complete remission (CR) in patients with acute myeloid leukemia (AML) and was resistant to consolidation and maintenance therapies, except for allogeneic stem cell transplantation (allo-SCT). However, the presence of postremission CH did not affect clinical outcomes.
Major finding: Following induction chemotherapies, 48% of patients had post-CR CH, and it persisted in 91% of patients during and postremission chemotherapies, but disappeared in 95% of patients after allo-SCT. However, the risk for relapse (P = .174) and nonrelapse mortality (P = .827) was similar in patients with vs. without post-CR CH.
Study details: Findings are from assessment of 164 patients with AML who achieved morphological CR following induction chemotherapies.
Disclosures: This work was supported by grants from the Cancer Prevention and Research Institute of Texas, Welch Foundation, University of Texas System STARS Award, Lyda Hill Foundation, Charif Souki Cancer Research Fund, Japan Society for the Promotion of Science, Sabin Family Foundation Fellowship, and various funding programs at the MD Anderson Cancer Center. The authors declared no conflicts of interest.
Source: Tanaka T et al. Blood. 2021 Jun 3. doi: 10.1182/blood.2020010483.